Eli Lilly and Company (SWX:LLY)
595.00
+5.00 (0.85%)
At close: Sep 4, 2025
Eli Lilly and Company Revenue
Eli Lilly and Company had revenue of $15.56B USD in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly and Company had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
12.70
Revenue / Employee
$1.13M
Employees
47,000
Market Cap
537.70B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Eli Lilly and Company News
- 1 day ago - Thousands in England unable to access weight loss jabs via GP, figures reveal - The Guardian
- 1 day ago - Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Benzinga
- 1 day ago - Lila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development - GlobeNewsWire
- 1 day ago - Alexandria Real Estate Equities, Inc. Named One of the World's Most Trustworthy Companies by Newsweek for the Second Consecutive Year - Benzinga
- 1 day ago - Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers - PRNewsWire
- 1 day ago - Where Will Eli Lilly Be in 3 Years? - The Motley Fool
- 1 day ago - Eli Lilly's Stock Fall Is An Opportunity - Seeking Alpha
- 2 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters